Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes
Authors:
Open Access
- 13 March 2012
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (4) , 840-847
Abstract
OBJECTIVE: To investigate the association of lipoprotein-associated phospholipase A2 (LpPLA2) mass and activity with incident cardiovascular disease (CVD) in a population with high prevalences of insulin resistance and diabetes, conditions for which epidemiological data remain sparse. RESEARCH DESIGN AND METHODS: We conducted a nested, case-control study (n = 1,008) within a population-based cohort of American Indians. Case subjects were defined by incidence of first-ever CVD up to 10 years later. Control subjects comprised participants free of CVD events during the follow-up period who were frequency matched to case subjects by age, sex, and diabetes status. LpPLA2 mass and activity were measured using commercially available assays. RESULTS: LpPLA2 mass and activity were moderately correlated with each other (r = 0.30), but only LpPLA2 activity exhibited moderate correlations with lipid fractions. After extensive adjustment for covariates, both LpPLA2 measures were significantly associated with incident CVD, but the relationship was inverse for LpPLA2 mass (highest versus lowest tertile, relative risk [RR] 0.55 [95% CI 0.39–0.79]) and positive for LpPLA2 activity (highest versus lowest tertile, 1.65 [1.12–2.42]). These associations were similar when participants with and without diabetes were examined separately. CONCLUSIONS: In this population-based cohort enriched with dysmetabolic phenotypes, LpPLA2 mass and activity showed divergent associations with CVD. The inverse relationship for LpPLA2 mass is contrary to observations from predominantly nondiabetic populations and will require independent replication. Whether this finding relates to redistribution of LpPLA2 to lipoprotein classes where it is less atherogenic or reflects incomplete measurement of LpPLA2 mass associated with altered lipoprotein composition in insulin resistance warrants further investigation.Keywords
This publication has 33 references indexed in Scilit:
- Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health StudyDiabetologia, 2010
- Lipoprotein‐associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortalityJournal of Internal Medicine, 2010
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010
- Lipoprotein-Associated Phospholipase A2 Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 DiabetesDiabetes, 2010
- Prevalence of Overweight and Obesity in the United States, 1999-2004JAMA, 2006
- C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of DiabetesCirculation, 2005
- Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart StudyDiabetic Medicine, 2004
- Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: The strong heart studyAmerican Heart Journal, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipidsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996